Regenosome Co., Ltd. (Headquarters: Minato-ku, Tokyo; President: Zentaro Sakuma), a venture company in the longevity field and a group company of Space Seed Holdings Inc. (Headquarters: Minato-ku, Tokyo; President: Kengo Suzuki), has jointly filed a patent for a bicelle formulation that stably encapsulates retinoids (a general term for vitamin A and its derivatives, with retinol being one type of retinoid). This patent is the result of joint research with Specially Appointed Associate Professor Noriyuki Uchida of the Department of Applied Chemistry at Tokyo University of Agriculture and Technology (Patent Application No. 2026-084416, Filing Date: May 19, 2026). Regenosome aims to implement research results into society and will use this patent as a starting point to advance product development and practical application in the healthcare field. Background: The usefulness of retinol and its handling difficulties Retinol (vitamin A) is a well-known beneficial ingredient in the healthcare field. However, it is generally known that its susceptibility to factors like air and light makes it difficult to maintain stability, and its usability also requires careful consideration, posing challenges for its application. Technologies that can deliver such ingredients stably and with consideration for skin gentleness have been in demand. About Bicelle Formulations "Bicelles" are drawing attention as one type of nano-sized formulation carrier for delivering beneficial ingredients. By encapsulating beneficial ingredients within the carrier, it is expected that the ingredients can be delivered while maintaining their stability. We have been advancing research on bicelle formulations that stably encapsulate retinoids, and the results of this research have been compiled into the current patent application. Application Overview Item Details Application Number Patent Application No. 2026-084416 Filing Date May 19, 2026 Applicants Regenosome Co., Ltd. / Space Seed Holdings Inc. / Tokyo U